Related references
Note: Only part of the references are listed.SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model
S. D. Baines et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
In Vivo Assessment of SMT19969 in a Hamster Model of Clostridium difficile Infection
William Weiss et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates
Ellie J. C. Goldstein et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Emergence and global spread of epidemic healthcare-associated Clostridium difficile
Miao He et al.
NATURE GENETICS (2013)
Gut Microbiota Patterns Associated with Colonization of Different Clostridium difficile Ribotypes
Jure Skraban et al.
PLOS ONE (2013)
Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
O. A. Cornely
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Can we identify patients at high risk of recurrent Clostridium difficile infection?
C. P. Kelly
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Profound Alterations of Intestinal Microbiota following a Single Dose of Clindamycin Results in Sustained Susceptibility to Clostridium difficile-Induced Colitis
Charlie G. Buffie et al.
INFECTION AND IMMUNITY (2012)
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
Oliver A. Cornely et al.
LANCET INFECTIOUS DISEASES (2012)
Succession in the Gut Microbiome following Antibiotic and Antibody Therapies for Clostridium difficile
Gregory L. Peterfreund et al.
PLOS ONE (2012)
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Thomas J. Louie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon
Mary C. Rea et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Changing Epidemiology of Clostridium difficile Infections
J. Freeman et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C-difficile Infection
Thomas J. Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Clostridium difficile infection: new developments in epidemiology and pathogenesis
Maja Rupnik et al.
NATURE REVIEWS MICROBIOLOGY (2009)
Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease
Wafa N. Al-Nassir et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Emergence of reduced susceptibility to metronidazole in Clostridium difficile
Simon D. Baines et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Clostridium difficile— More Difficult Than Ever
Ciarán P. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile -: Associated diarrhea, stratified by disease severity
Fred A. Zar et al.
CLINICAL INFECTIOUS DISEASES (2007)
Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model
SD Baines et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Inhibition of Clostridium difficile strains by intestinal Lactobacillus species
P Naaber et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2004)
Antibiotic-associated diarrhea
JG Bartlett
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
